Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumors 1Pancreatic Neoplasms 1Haematological Malignancies 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
MSC1992371A × Clear all
NCT00391521 2014-01-30

AS703569 Phase I in Patients With Solid Tumours

EMD Serono

Phase 1 Completed
104 enrolled
Other solid neoplasm

Solid Tumors

NCT01097512 2014-01-30

AS703569 and Gemcitabine Combination in Advanced Malignancies

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
66 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01080664 2013-10-22

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

EMD Serono

Phase 1 Terminated
124 enrolled

Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡